CERRI; Alberto

Patent Applications and Registrations

Patent applications and USPTO patent grants for CERRI; Alberto.The latest application filed is for "17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure".

Company Profile

0.14.9

CERRI; Alberto - Milano IT
Cerri; Alberto - Milan N/A IT
Cerri; Alberto - Gessate IT
Cerri, Alberto - Gessate MI
Cerri; Alberto - Vigevano Pavia IT

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
17beta-heterocyclyl-digitalis Like Compounds For The Treatment Of Heart Failure App 20210283147 - CERRI; Alberto ; et al.	2021-09-16
Crystalline rostafuroxin Grant 9,127,037 - Cerri , et al. September 8, 2	2015-09-08
Diterpenoid derivatives endowed of biological properties Grant 8,822,692 - Cerri , et al. September 2, 2	2014-09-02
Aminooxime derivatives of 2- and/or 4-substituted androstanes and androstenes as medicaments for cardiovascular disorders Grant 8,664,210 - Cerri , et al. March 4, 2	2014-03-04
Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders Grant 8,609,644 - Cerri , et al. December 17, 2	2013-12-17
Diterpenoid Derivatives Endowed Of Biological Properties App 20130310423 - Cerri; Alberto ; et al.	2013-11-21
Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders Grant 8,536,160 - Cerri , et al. September 17, 2	2013-09-17
Amino derivatives of beta-homoandrostanes and beta-heteroandrostanes Grant 8,022,203 - Cerri , et al. September 20, 2	2011-09-20
Amino Derivatives Of Androstanes And Androstenes As Medicaments For Cardiovascular Disorders App 20110053902 - Cerri; Alberto ; et al.	2011-03-03
Aminooxime Derivatives Of 2- And/or 4-substituted Androstanes And Androstenes As Medicaments For Cardiovascular Disorders App 20100324003 - Cerri; Alberto ; et al.	2010-12-23
Azaheterocyclyl Derivatives Of Androstanes And Androstenes As Medicaments For Cardiovascular Disorders App 20090275542 - Cerri; Alberto ; et al.	2009-11-05
Amino Derivatives Of Beta-homoandrostanes And Beta-heteroandrostanes App 20090209506 - Cerri; Alberto ; et al.	2009-08-20
Crystalline Rostafuroxin App 20080300228 - Cerri; Alberto ; et al.	2008-12-04
Process for preparing R-(-)carnitine from S-(-)-chlorosuccinic acid or from a derivative thereof Grant 7,247,747 - Melloni , et al. July 24, 2	2007-07-24
Process for preparing R-(-)-carnitin from S-(-)-chlorosuccinic acid or from a derivative thereof Grant 6,984,739 - Melloni , et al. January 10, 2	2006-01-10
Process for preparing R-(-)carnitine from S-(-)-chlorosuccinic acid or from a derivative thereof App 20050245762 - Melloni, Piero ; et al.	2005-11-03
Process for preparing R-(-)-carnitin from S-(-)-chlorosuccinic acid or from a derivative thereof App 20040102645 - Melloni, Piero ; et al.	2004-05-27
Process for preparing R-(-) -carnitine from S-(-)-chlorosuccinic acid or from a derivative thereof Grant 6,677,476 - Melloni , et al. January 13, 2	2004-01-13
Psychotropic perhydroazacycloalka [1,2-A] imidazole derivatives Grant 5,053,422 - Pinza , et al. October 1, 1	1991-10-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.